Sanfilippo Syndrome Drug Discovery Service

Creative Biolabs provides custom Sanfilippo syndrome drug discovery services for programs that need a mechanistically defined MPS III model, quantitative evidence of heparin sulfate correction, and a preclinical workflow that connects target engagement to CNS-relevant outcomes. The service can support Sanfilippo types A, B, C, and D; target validation; assay development; small-molecule and biologic screening; enzyme- or gene-restoration concepts; substrate reduction; lysosomal trafficking and pharmacological-chaperone studies; blood-brain barrier delivery strategies; neuroinflammation research; and in vivo efficacy testing.

Sanfilippo Drug Discovery Program Strategy

Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), comprises four autosomal recessive lysosomal storage disorders that share impaired degradation of heparan sulfate but arise from defects in different enzymes. This shared substrate biology makes cross-subtype readouts possible, while the distinct enzyme defect determines which rescue strategy, target-engagement assay, and control material are appropriate. For example, a program restoring NAGLU activity in MPS IIIB requires a different biochemical confirmation package from a program designed to suppress heparan sulfate synthesis across multiple MPS III subtypes.

Program design begins by defining whether the key decision is target validation, hit identification, lead optimization, CNS delivery, pharmacodynamic confirmation, or in vivo efficacy.

• Modality and target: Define whether the candidate is an enzyme, gene or RNA therapy, small molecule, substrate-reduction agent, chaperone, trafficking modifier, neuroprotective agent, anti-inflammatory intervention, or BBB-delivery construct.
• Biological level of rescue: Separate enzyme or target engagement from substrate clearance, lysosomal normalization, neural-cell rescue, and organism-level function. A candidate should not be advanced on a single downstream marker when the primary biochemical defect can be measured directly.
• Disease stage and intervention window: Early biochemical correction and treatment of established neuropathology answer different questions. Cell age, model age, dosing schedule, and sampling time are therefore set prospectively.
• Comparator strategy: Disease controls, unaffected or isogenic controls, vehicle groups, positive-control rescue, and modality-specific comparators can be incorporated when they improve interpretation.
• Decision thresholds: Where feasible, the study plan specifies assay acceptance limits, minimum effect size, reproducibility expectations, exposure requirements, and the criteria that trigger secondary confirmation.

Programs that require a broader lysosomal-storage framework can be coordinated with the Mucopolysaccharidosis Drug Discovery Service.

Build Cellular, Neural, BBB, and In Vivo Disease Models

A fibroblast or engineered cell line can be efficient for enzyme activity and primary substrate work, but it may not reproduce the neuronal, glial, or barrier biology needed to evaluate CNS rescue. Conversely, an animal study is unnecessarily resource-intensive if the candidate has not yet shown biochemical correction in a tractable cellular system. Creative Biolabs can configure a staged model ladder so that each model answers a defined question and failed candidates are identified before the most complex study tier.

Cellular and iPSC-Based Models

Cellular models can be built from patient-derived material, client-provided cells, engineered disease/control backgrounds, or iPSCs selected around the relevant genotype. Primary qualification can include genotype or construct confirmation, deficient enzyme activity, heparan sulfate or disease-associated HS fragment accumulation, lysosomal changes, and reproducibility across passages or differentiations. For genetic rescue experiments, corrected or add-back conditions are particularly useful because they link a phenotype to the causal defect rather than to donor background.

When patient- or genotype-specific neural systems are needed, projects can be connected with Custom Disease/Control iPSC Generation and downstream neural differentiation workflows.

Neurons, astrocytes, and microglia can be incorporated separately or in co-culture depending on the mechanism. Neuronal models are useful for lysosomal burden, viability, neurite or synaptic phenotypes, and target-engagement studies. Astrocytes and microglia can add a non-cell-autonomous component when inflammatory signaling, lysosomal stress, or glial responses are part of the hypothesis. A co-culture design is most informative when each cell type can be independently qualified and the readout distinguishes rescue of neuronal function from a general reduction in cell stress.

BBB and CNS Delivery Models

CNS-directed therapies often fail because a molecule that is active in a cell-free or peripheral system does not achieve sufficient brain exposure. In vitro barrier models can therefore be introduced before in vivo efficacy to compare transport, stability, endothelial response, and post-transcytosis activity.

For delivery-focused programs, see the iPSC-derived BBB Model Generation Service and the NeuroPro Anti-NAGLU BBB Shuttle Protein as a related research reagent for NAGLU-oriented work.

In Vivo Disease Models

In vivo studies can use project-appropriate genetic models of Sanfilippo syndrome to examine biochemical correction across brain regions, CSF and peripheral tissues; dose and route dependence; neuropathology; neuroinflammation; behavior; and durability of response. The exact model is selected according to subtype, target, age of onset, route of administration, and the endpoint window required by the candidate. Because progressive lysosomal storage can alter multiple tissues, baseline age and cohort balance are controlled carefully, and terminal tissue collection is planned around the pharmacodynamic hypothesis rather than added at the end as a generic panel.

Broader study planning can also use Creative Biolabs Animal Model Development capabilities when a customized in vivo platform is required.

Measure HS Storage, Lysosomal Rescue, Neuroinflammation, and CNS Function

Primary Biochemical and Lysosomal Readouts

• Deficient enzyme activity can be quantified in cells, lysates, CSF, brain regions, or peripheral tissues using a project-appropriate substrate and assay format. For enzyme-restoration programs, activity should be interpreted together with uptake, localization, and persistence rather than as a stand-alone number.
• Total heparan sulfate and disease-associated HS fragments or non-reducing ends can provide direct pharmacodynamic evidence of substrate correction. The analytical method, sample normalization, lower limit of quantification, and tissue handling are matched to the expected range.
• Lysosomal burden can be assessed with markers such as LAMP1, organelle imaging, lysosomal-enzyme changes, or related measures selected for the model. A successful biochemical rescue should reduce disease-associated storage rather than merely alter one lysosomal marker.
• Secondary lipid, autophagy, or protein-homeostasis changes can be incorporated when the mechanism or literature supports them. These endpoints are typically positioned after the primary substrate readout so that downstream effects are interpreted in the context of actual pathway correction.

Neuroinflammation and Neural-System Readouts

Microglial and astrocytic responses can become prominent in neuropathic MPS models. Depending on the study, readouts may include microglial activation state, astrocytosis, cytokines and chemokines, immune-cell composition, morphology, phagocytic or inflammatory responses, and region-specific histopathology. These data can help distinguish a candidate that corrects the storage defect from one that primarily suppresses a secondary inflammatory pathway.

Related capabilities include the Microglia Activation Assay Service and Immune Cell Profiling in Neurological Diseases. Neuronal endpoints can include viability, morphology, neurite structure, synaptic or electrophysiological measures, selected protein-pathology markers, and region-specific histology.

Exposure, Distribution, and Pharmacodynamic Alignment

For CNS candidates, the relationship between exposure and pharmacodynamics is often more informative than either measure alone. Blood, plasma, CSF, brain regions, liver, spleen, and other tissues can be sampled at planned intervals to determine whether a dose that produces systemic exposure also reaches the pharmacologically relevant compartment. For proteins or gene-delivery approaches, regional enzyme activity or transgene expression can be mapped against HS reduction and histopathology. For small molecules, concentration-response relationships can be linked to substrate reduction or pathway markers.

Configure Candidate Screening, PK/PD, and Decision Gates

Drug discovery programs become difficult to compare when every candidate is tested in a different model, at a different disease stage, or with a different endpoint panel. A staged workflow helps maintain a common decision framework while allowing modality-specific assays. Creative Biolabs can build the screen around one or two high-information primary readouts and reserve more complex neural or in vivo endpoints for confirmed candidates.

Small Molecules and Substrate-Reduction Programs

A small-molecule screen can begin with a scalable biochemical or cellular phenotype, followed by concentration-response confirmation and counterscreens for general toxicity, growth effects, or assay interference. Substrate-reduction approaches can be evaluated by measuring the balance between reduced HS synthesis and acceptable cell health. For molecules intended to act broadly across MPS III subtypes, cross-genotype testing can determine whether the effect depends on residual activity of one defective enzyme or instead acts on a shared pathway.

Enzyme, Gene, and RNA Restoration Programs

Restoration strategies require evidence that the delivered product is not only present but functionally competent in the relevant compartment. A program may therefore combine expression or enzyme activity, intracellular uptake, lysosomal localization, HS correction, regional distribution, durability, and downstream disease markers. Cross-correction can be studied where secreted enzyme or vector transduction of one cell population is expected to benefit neighboring cells. Dose selection can be informed by the amount of target activity needed to cross a biochemical threshold rather than by exposure alone.

BBB-Enabled Biologics and Delivery Technologies

For large biologics, BBB delivery is part of the pharmacology. A candidate can be ranked on transport, stability, receptor-mediated uptake, retention of enzymatic or binding activity after transit, brain distribution, and tissue pharmacodynamics. In vivo studies can compare routes of administration and dose levels while maintaining the same biochemical endpoint hierarchy. This avoids interpreting a delivery failure as a failure of the therapeutic mechanism itself.

Related Research

CNS NAGLU Delivery Can Drive Marked HS Clearance

Aoyagi-Scharber and colleagues evaluated intracerebroventricular delivery of NAGLU-IGF2 (BMN 250) in Naglu-deficient mice. Four 100 microgram doses over two weeks produced high brain NAGLU activity and broad uptake. Twenty-four hours after the final infusion, total HS was reduced by 87.1% and disease-specific HS non-reducing ends by 98.5% relative to vehicle-treated MPS IIIB mice. The study also described reductions in secondary lysosomal defects and neuropathology across brain regions. This provides a useful example of a translational assay chain in which delivery, enzyme activity, primary substrate clearance, and downstream pathology can be evaluated within the same program.

Fig. 1 Reduction of Lysosomal Storage and Elevated β-hexosaminidase Activity by BMN 250.^1,2

Frequently Asked Questions

1. Which Sanfilippo subtypes can be supported?

   Programs can be designed for MPS IIIA, IIIB, IIIC, or IIID. The subtype determines the defective enzyme, genetic model, target-engagement assay, and most informative rescue controls, while shared heparan-sulfate and lysosomal endpoints can support cross-subtype comparisons when appropriate.

2. What models are suitable for early Sanfilippo drug discovery?

   Early work can use engineered or patient-derived cells for enzyme activity, heparan-sulfate accumulation, lysosomal phenotypes, and target validation. iPSC-derived neurons, astrocytes, microglia, co-cultures, or BBB models can be added when CNS cell biology or delivery is central to the hypothesis. In vivo genetic models are typically reserved for candidates that have passed cell-based confirmation.

3. How is therapeutic rescue measured in a Sanfilippo model?

   A strong package separates target engagement from disease modification. Depending on the modality, readouts can include deficient enzyme activity, total or disease-associated heparan sulfate, lysosomal markers, neural-cell phenotypes, neuroinflammation, brain-region pharmacodynamics, histopathology, behavior, and durability after dosing.

4. Can Creative Biolabs support enzyme replacement or gene-therapy concepts?

   Yes. Projects can be configured to measure expression or enzyme activity, cellular uptake, lysosomal targeting, CNS distribution, heparan-sulfate correction, secondary pathology, and dose-response relationships. The specific package is adapted to the route of administration and the expected mechanism of cross-correction or transduction.

5. Can Sanfilippo candidates be evaluated for blood-brain barrier delivery?

   Yes. In vitro BBB models and in vivo exposure studies can be incorporated to compare transport, stability, retained activity, brain or CSF exposure, and downstream pharmacodynamic correction. Delivery data are interpreted together with the therapeutic readout so that poor CNS exposure is not confused with lack of intrinsic target activity.

6. Can neuroinflammation be included as an efficacy endpoint?

   Yes. Depending on the model, the study can assess microglial activation, astrocytosis, cytokines, immune-cell profiles, or region-specific inflammatory histology. These are usually treated as secondary disease markers and interpreted alongside primary heparan-sulfate or enzyme-correction endpoints.

7. Is it possible to screen small molecules for substrate reduction or lysosomal rescue?

   Yes. A screen can be built around a scalable biochemical or cellular phenotype, followed by concentration-response confirmation, cytotoxicity or interference counterscreens, orthogonal heparan-sulfate or lysosomal assays, and neural-cell confirmation for selected hits.

8. What information is needed to design a custom Sanfilippo project?

   Useful inputs include the MPS III subtype or genotype, candidate modality, available cells or vectors, intended route, target tissue, primary decision endpoint, desired scale, compounds or biologics, comparator strategy, study stage, and any required CNS delivery or behavioral endpoints. If these are not fixed, a feasibility phase can define the model and assay sequence.

9. Can a program combine cell-based screening with in vivo validation?

   Yes. A staged program can use biochemical or cellular assays for initial ranking, then confirm selected candidates in neural models, BBB systems, and disease-relevant in vivo models. Keeping a common target-engagement and substrate-correction endpoint across tiers improves continuity when candidates move between models.

References

1. Aoyagi-Scharber, Mika, et al. "Clearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice." Molecular Therapy - Methods & Clinical Development, vol. 6, 2017, pp. 43-53. https://doi.org/10.1016/j.omtm.2017.05.009
2. Distributed under Open Access license CC BY 4.0, without modification.